Ahead Therapeutics, a company promoted by ZBM Business Connect in 2017, is preparing for a new funding round to start the clinical trials. The first round amounted to a total of 2 million euros.
The biotech aims to develop new drugs against autoimmune diseases (type 1 diabetes, multiple sclerosis, celiac disease, pemphigus and thyroiditis). Its technology comes from the Germans Trias i Pujol Research Institute (IGTP), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Catalan Institution for Research and Advanced Studies (ICREA).
ZBM Business Connect, division of ZBM Patents & Trademarks and a CataloniaBio & HealthTech member, provided advice on the transfer of technology of Ahead and put forward Martí Dalmases as executive director.
Photo: Martí Dalmases - ZBM Business Connect
Comments